Built around your programme
Expert-led decisions, connected data and a practical route to the next meaningful experiment.
Bispecific antibodies are engineered therapeutic molecules designed to simultaneously bind two distinct antigens or epitopes. This dual targeting capability enables powerful and differentiated mechanisms of action, including immune cell redirection, enhanced tumor selectivity, dual checkpoint inhibition, and coordinated modulation of multiple disease pathways.
Bispecific antibodies are engineered therapeutic molecules designed to simultaneously bind two distinct antigens or epitopes. This dual targeting capability enables powerful and differentiated mechanisms of action, including immune cell redirection, enhanced tumor selectivity, dual checkpoint inhibition, and coordinated modulation of multiple disease pathways.

By integrating multiple biological functions into a single molecule, bispecific antibodies offer new possibilities across oncology, immunology, infectious disease, and other complex disease areas. This unlocks therapeutic strategies that are not achievable with conventional monospecific antibodies alone.
We deliver tailored bispecific antibody design strategies grounded in decades of antibody engineering expertise and a deep understanding of complex molecular architectures.
We guide optimal format selection (IgG-like or fragment-based) based on your biological targets, intended mechanism of action, and therapeutic context.
Our team designs and optimizes Fc regions to achieve the desired balance of half-life, effector function, and manufacturability aligned with your program goals.
We ensure balanced expression and accurate chain pairing through optimized vector design and robust expression systems.
Advanced sequence liability screening and structure-based analysis identify potential risks early, supporting informed design decisions and streamlined humanization.
We provide sequence engineering, codon optimization, and CDR grafting to enhance compatibility, reduce immunogenicity, and prepare your molecule for downstream development.
Designing bispecific antibodies is complex. Even with a strong concept, developers frequently encounter hurdles such as:
These challenges can slow development and compromise functionality. That’s why working with Fusion Antibodies matters. With deep expertise in structural biology, rational engineering, and proprietary in silico tools, we know how to navigate these difficulties and deliver stable, functional bispecifics tailored to your therapeutic goals.
| Format | Description |
|---|---|
| Knob-in-Hole IgG | Facilitates correct heavy chain heterodimerization using structural mutations. |
| CrossMab | Enables light chain pairing control by domain swapping. |
| Dual Variable Domain (DVD-Ig) | Two variable regions stacked on a single chain for dual binding. |
| scFv-Fc Fusion | Combines small size with Fc stability and function. |
| Tandem scFv (BiTE) | Two scFvs connected for T cell redirection, ideal for immuno-oncology. |
| IgG-scFv | |
| Two-in-One Antibodies | Single binding site engineered to recognize two distinct antigens. |

From design through to transient gene expression and bespoke purification, we optimise challenging molecules for performance, scalability, and manufacturability
Expert-led decisions, connected data and a practical route to the next meaningful experiment.
Start with the biology, share the context and move forward with confidence.
Yes. Our teams are designed to share context across discovery, engineering and supply.
Share the useful starting details and your enquiry will be sent securely to Fusion’s scientific team.